This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gordon Mansergh, MA, MEd; Anne C. Haddix, PhD; Richard W. Steketee, MD, MPH; R. J. Simonds, MD
Centers for Disease Control and Prevention Atlanta, Ga

JAMA. 1996;276(19):1552-1553.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—As Drs Nicoll and Newell suggest, short-course zidovudine treatment to reduce mother-to-child transmission of HIV may not be cost-effective in all settings. However, according to our model, such treatment (if shown to be efficacious) may be cost-effective from a societal perspective across a wide range of per capita gross national products, particularly in areas with high HIV prevalence among childbearing women. Considerations for its use in particular settings will depend on the relative importance of HIV prevention among other health needs.

We share the concern that increased postnatal HIV transmission in breast-feeding populations could offset some of the benefit achieved by prenatal and perinatal HIV transmission prevention with zidovudine or other strategies. Our model adjusts the number of children at risk for postpartum HIV infection based on changes in prenatal and perinatal HIV transmission rates. For example, in a population in which 100% of the infants are breast-fed with a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?